Avalo Therapeutics Inc (AVTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Avalo Therapeutics Inc (AVTX) has a cash flow conversion efficiency ratio of -0.179x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-16.36 Million) by net assets ($91.55 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Avalo Therapeutics Inc balance sheet independence to measure how much of total assets are equity-financed.
Avalo Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Avalo Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check AVTX cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Avalo Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Avalo Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Divgi Torqtransfer Systems Limited
NSE:DIVGIITTS
|
0.016x |
|
Public Policy Holding Company, Inc. Common Stock
NASDAQ:PPHC
|
0.197x |
|
Balmer Lawrie & Company Limited
NSE:BALMLAWRIE
|
-0.035x |
|
Honey Hope Honesty Enterprise Co Ltd
TWO:8043
|
-0.009x |
|
Lime Technologies AB (publ)
ST:LIME
|
0.132x |
|
Chinese Maritime Transport Ltd
TW:2612
|
0.047x |
|
Oceania Healthcare Ltd
AU:OCA
|
0.064x |
|
Merlin, Inc.
NASDAQ:MRLN
|
0.025x |
Annual Cash Flow Conversion Efficiency for Avalo Therapeutics Inc (2012–2024)
The table below shows the annual cash flow conversion efficiency of Avalo Therapeutics Inc from 2012 to 2024. For the full company profile with market capitalisation and key ratios, see Avalo Therapeutics Inc market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $133.03 Million | $-49.06 Million | -0.369x | +91.22% |
| 2023-12-31 | $7.30 Million | $-30.68 Million | -4.200x | -271.39% |
| 2022-12-31 | $-10.91 Million | $-26.75 Million | 2.451x | +179.80% |
| 2021-12-31 | $23.08 Million | $-70.89 Million | -3.071x | -86.09% |
| 2020-12-31 | $24.56 Million | $-40.54 Million | -1.650x | -81.10% |
| 2019-12-31 | $21.00 Million | $-19.13 Million | -0.911x | -509.13% |
| 2018-12-31 | $20.91 Million | $-3.13 Million | -0.150x | -133.29% |
| 2017-12-31 | $27.86 Million | $12.52 Million | 0.449x | +100.64% |
| 2016-12-31 | $207.00K | $-14.57 Million | -70.402x | -8963.27% |
| 2015-12-31 | $13.08 Million | $-10.16 Million | -0.777x | -231.80% |
| 2014-12-31 | $-26.33 Million | $-15.52 Million | 0.589x | -8.42% |
| 2013-12-31 | $-17.85 Million | $-11.49 Million | 0.644x | +158.73% |
| 2012-12-31 | $8.48 Million | $-9.29 Million | -1.096x | -- |
About Avalo Therapeutics Inc
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. Its lead asset includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its nam… Read more